Rodman & Renshaw has published a report on Abiomed Inc ABMD upgrading the stock as it reached the PT.
In the report, Rodman & Renshaw wrote, "We are upgrading ABMD to a Market Perform rating. Our earlier rating was a Market UnderPerform with a $10 PT. ABMD stock recently hit our PT and since has moved slightly up. Our ratings change is simply a reflection of the stock price move and nothing to do with fundamentals."
Rodman & Renshaw upgraded Abiomed from Market Underperform to Market Perform with a price target of $10.00. Rodman & Renshaw closed Friday at $11.66.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in